Patents by Inventor John H. Sampson

John H. Sampson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11813298
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
    Type: Grant
    Filed: July 5, 2022
    Date of Patent: November 14, 2023
    Assignee: Duke University
    Inventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
  • Patent number: 11684662
    Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.
    Type: Grant
    Filed: July 11, 2021
    Date of Patent: June 27, 2023
    Assignee: Duke University
    Inventors: John H Sampson, Duane A Mitchell, Kristen A Batich, Michael D Gunn
  • Publication number: 20220401552
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Application
    Filed: June 15, 2022
    Publication date: December 22, 2022
    Applicant: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell
  • Publication number: 20220387582
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Application
    Filed: May 17, 2022
    Publication date: December 8, 2022
    Applicant: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell
  • Publication number: 20220378906
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Application
    Filed: May 31, 2022
    Publication date: December 1, 2022
    Applicant: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell
  • Publication number: 20220370602
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Application
    Filed: May 6, 2022
    Publication date: November 24, 2022
    Applicant: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell
  • Publication number: 20220339223
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
    Type: Application
    Filed: July 5, 2022
    Publication date: October 27, 2022
    Inventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
  • Patent number: 11406677
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: August 9, 2022
    Assignee: Duke University
    Inventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
  • Patent number: 11389530
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: July 19, 2022
    Assignee: Duke University
    Inventors: John H Sampson, Duane A Mitchell
  • Patent number: 11376322
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: July 5, 2022
    Assignee: Duke University
    Inventors: John H Sampson, Duane A Mitchell
  • Patent number: 11364295
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: June 21, 2022
    Assignee: Duke University
    Inventors: John H Sampson, Duane A Mitchell
  • Patent number: 11351248
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: June 7, 2022
    Assignee: Duke University
    Inventors: John H Sampson, Duane A Mitchell
  • Publication number: 20220031827
    Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.
    Type: Application
    Filed: July 11, 2021
    Publication date: February 3, 2022
    Applicant: Duke University
    Inventors: John H Sampson, Duane A Mitchell, Kristen A Batich, Michael D Gunn
  • Publication number: 20210309750
    Abstract: Enhancing the delivery of therapeutic, diagnostic and other useful compounds to the brain and other tissues permits more effective use of reagents and use of lower doses. Our method permits enhanced delivery of molecules that are diagnostically, therapeutically, or otherwise useful to specific tissues in the body, including the central nervous system (CNS). Large, hydrophilic molecules, such as antibodies, are typically restricted from entering the CNS by the blood-brain barrier and fail to accumulate to therapeutic levels within the brain. Our method permits enhanced penetrance of the CNS by peripherally administered antibodies. Our method can be applied to enhance the delivery of a variety of therapeutic, diagnostic, and otherwise useful molecules to any tissue, many of which have previously been clinically ineffective due to poor tissue penetrance.
    Type: Application
    Filed: August 7, 2019
    Publication date: October 7, 2021
    Inventors: John H. Sampson, Patrick C. Gedeon, Bryan D. Choi
  • Patent number: 11071777
    Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: July 27, 2021
    Assignee: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell, Kristen A. Batich, Michael D. Gunn
  • Publication number: 20210000943
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Application
    Filed: July 23, 2020
    Publication date: January 7, 2021
    Applicant: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell
  • Publication number: 20210000944
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Application
    Filed: July 24, 2020
    Publication date: January 7, 2021
    Applicant: Duke University
    Inventors: John H Sampson, Duane A Mitchell
  • Publication number: 20200405795
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
    Type: Application
    Filed: September 10, 2020
    Publication date: December 31, 2020
    Applicant: Duke University
    Inventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
  • Publication number: 20200345837
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Application
    Filed: July 22, 2020
    Publication date: November 5, 2020
    Applicant: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell
  • Patent number: 10799543
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: October 13, 2020
    Assignee: Duke University
    Inventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman